Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 2/20 | 0.48 |
| ▸ | LIPE | Q05469 | 3/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514570 | 0.89 | PDE9A (0.61) | PDE9ATYK2PDE5AMEN1KMT2A | |
| SCHEMBL4515391 | 0.89 | TYK2 (0.46) | PDE9ATYK2PTGS2PDE5ATRPV1 | |
| SCHEMBL4510948 | 0.89 | TYK2 (0.53) | PDE9ATYK2PTGS2PDE5AMEN1 | |
| SCHEMBL4502029 | 0.88 | POLB (0.49) | PDE9ATYK2PTGS2PDE5AMEN1 | |
| SCHEMBL4513616 | 0.84 | PDE9A (0.51) | PDE9AEPHX2PDE5A | |
| SCHEMBL4505445 | 0.84 | TYK2 (0.46) | PDE9ATYK2PTGS2PDE5AMEN1 | |
| SCHEMBL4511659 | 0.84 | PDE9A (0.50) | PDE9ATYK2PTGS2PDE5ATRPV1 | |
| SCHEMBL4512344 | 0.84 | TYK2 (0.48) | PDE9ATYK2PTGS2PDE5AMEN1 | |
| SCHEMBL4515587 | 0.84 | TYK2 (0.46) | PDE9ATYK2PTGS2PDE5AMEN1 | |
| SCHEMBL4513101 | 0.83 | MAPK1 (0.51) | PDE9ATYK2PDE5AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | claimed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | claimed |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE9A 40/4885LIPE 2334/4885TYK2 4707/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | PDE9A 29/4885LIPE 2071/4885TYK2 4749/4885 |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | PDE9A 13/4885LIPE 2059/4885TYK2 3816/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE9A 40/4885LIPE 2334/4885TYK2 4707/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | PDE9A 34/4885LIPE 2038/4885TYK2 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.